Library of antigen-binding molecules including modified antibody variable region

Patent metadata

Field	Value
Publication number	US-11154615-B2
Application number	US-201515525603-A
Country	US
Kind code	B2
Filing date	Nov 11, 2015
Priority date	Nov 11, 2014
Publication date	Oct 26, 2021
Grant date	Oct 26, 2021

Abstract

The present inventors have successfully prepared a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, the antigen-binding molecules each comprising an antibody variable region that has binding activity against a first antigen and a second antigen different from the first antigen, but does not bind to the first antigen and the second antigen at the same time. Use of the library of the present invention allows the obtainment of a variable region having enhanced ability to bind to the first antigen and the production of a bispecific antibody against the first antigen and a cancer antigen. Moreover, the present inventors have also successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against three different antigens, but does not bind to these antigens at the same time.

First claim

The invention claimed is:

1. A library comprising a plurality of antigen-binding polypeptide molecules that differ from each other in amino acid sequence, wherein
each antigen-binding polypeptide molecule of the plurality comprises an antibody variable region that can bind to a first antigen and a second antigen, but not at the same time;
one of the antigens is CD3;
the other antigen is a molecule expressed on the surface of a naturally occurring immunocyte and is not CD3;
the antibody variable regions of the plurality of antigen-binding polypeptide molecules differ from each other in amino acid sequence;
each antibody variable region comprises a VH comprising the amino acid sequence of SEQ ID NO: 96 or an altered SEQ ID NO: 96, the alterations in SEQ ID NO: 96 being at one or more positions selected from Kabat numbering positions 31, 52b, 52c, 53, 54, 56, 57, 61, 98, 99, 100, 100a, 100b, 100c, 100d, 100e, 100f, and 100g; and
each antibody variable region comprises a VL comprising the amino acid sequence of SEQ ID NO: 53 or an altered SEQ ID NO: 53, the alterations in SEQ ID NO: 53 being at one or more positions selected from Kabat numbering positions 24, 25, 26, 27, 27a, 27b, 27c, 27e, 30, 31, 33, 34, 51, 52, 53, 54, 55, 56, 74, 77, 89, 90, 92, 93, 94, and 96.

2. The library of claim 1 , wherein the differences in sequence between at least some of the antibody variable regions include a peptide present in a VH loop, the loop being within or comprising part or all of VH CDR1, VH CDR2, VH CDR3, or VH FR3, wherein the peptide binds to one of the antigens.

3. The library of claim 2 , wherein the peptide is present within the VH CDR3 of at least some of the antibody variable regions.

4. The library of claim 1 , wherein the antigen that is not CD3 is selected from the group consisting of: an FcγR, a toll like receptor (TLR), a lectin, an immune checkpoint molecule, a tumor necrosis family receptor (TNFR) superfamily molecule, and a natural killer (NK) cell receptor molecule.

5. The library of claim 1 , wherein the antigen-binding polypeptide molecules are fusion polypeptides, each comprising a portion of a viral coat protein.

6. A method for generating the library of claim 1 , the method comprising:
(a) identifying a template sequence that is an amino acid sequence of a starting antibody variable region that binds to the first antigen;
(b) identifying a set of different amino acid alterations that can be made to the template sequence to produce a set of different variant sequences, each variant sequence having at least one amino acid alteration compared to the template sequence, wherein each alteration satisfies one or more of the following conditions (i)-(iii):
(i) the alteration does not substantially affect binding to the first antigen,
(ii) the alteration does not substantially increase binding to extracellular matrix (ECM), and
(iii) the alteration is an insertion of 1 to 25 contiguous amino acid residues into a VH CDR1, VH CDR2, VH CDR3, or VH FR3 of the template sequence;

(c) generating a nucleic acid library comprising nucleic acids that encode antigen-binding polypeptide molecules comprising antibody variable regions represented by the set of different variant sequences; and
(d) expressing the nucleic acids, thereby producing the library of antigen-binding polypeptide molecules.

7. The method of claim 6 , wherein the template sequence comprises one or both of SEQ ID NOs: 96 and 53.

8. The method of claim 6 , wherein the antigen-binding polypeptide molecules encoded by the nucleic acids of (c) further comprise at least a portion of a viral coat protein.

9. A method of selecting an antigen-binding polypeptide molecule, the method comprising:
(a) contacting the antigen-binding polypeptide molecules of the library of claim 1 with the second antigen;
(b) recovering antigen-binding polypeptide molecules that bind to the second antigen;
(c) selecting, from the antigen-binding polypeptide molecules recovered in (b), an antigen-binding polypeptide molecule comprising a variable region that binds to the first and second antigens, but does not bind to both at the same time.

10. The method of claim 9 , wherein the antigen that is not CD3 is selected from the group consisting of: an FcγR, a TLR, a lectin, an IgA, an immune checkpoint molecule, a TNF superfamily molecule, a TNFR superfamily molecule, and a NK cell receptor molecule.

11. A method for selecting an antibody variable region that binds more strongly to an antigen than does a control antigen-binding polypeptide molecule, the method comprising:
(a) contacting the antigen-binding polypeptide molecules of the library of claim 1 with the first antigen;
(b) recovering antigen-binding polypeptide molecules that bind to the first antigen;
(c) providing a control antigen-binding molecule that binds to the first antigen;
(d) of the antigen-binding polypeptide molecules recovered in (b), identifying an antigen-binding polypeptide molecule that binds more strongly to the first antigen than does the control antigen-binding polypeptide molecule; and
(e) selecting the antigen-binding polypeptide molecule identified in (d).

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Igawa Tomoyuki
• Kadono Shojiro
• Hironiwa Naoka
• Sakurai Mika

Classifications

• C40B40/10 Primary

  Libraries containing peptides or polypeptides, or derivatives thereof · CPC title

• C07K16/2848

  against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61 · CPC title

• C40B30/04

  by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding · CPC title

• C07K2317/35

  Valency · CPC title

• C07K16/2875

  against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title